Related Experiment Video
Updated: Jun 13, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
A claudin-targeting molecule as an inhibitor of tumor metastasis
Rie Saeki1, Masuo Kondoh, Hideki Kakutani
1Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan.
Abstract:
Tumor metastasis of epithelium-derived tumors is the major cause of death from malignant tumors. Overexpression of claudin is observed frequently in malignant tumors. However, claudin-targeting antimetastasis therapy has never been investigated. We previously prepared a claudin-4-targeting antitumor molecule that consisted of the C-terminal fragment of Clostridium perfringens enterotoxin (C-CPE) fused to protein synthesis inhibitory factor (PSIF) derived from Pseudomonas exotoxin. In the present study, we investigated whether claudin CPE receptors can be a target for tumor metastasis by using the C-CPE-fused PSIF as a claudin-targeting agent. One of the most popular murine metastasis models is the lung metastasis of intravenously injected B16 cells. Therefore, we first investigated the effects of the C-CPE-fused PSIF on lung metastasis of claudin-4-expressing B16 (CL4-B16) cells. Intravenous administration of the C-CPE-fused PSIF suppressed lung metastasis of CL4-B16 cells but not B16 cells. Injection of C-CPE-fused PSIF also inhibited tumor growth and spontaneous lung metastasis of murine breast cancer 4T1 cells inoculated into the subcutis. Treatment with C-CPE-fused PSIF did not show apparent side effects in mice. These findings indicate that claudin targeting may be a novel strategy for inhibiting some tumor metastases.
Insights
Claudin targeting shows promise for inhibiting tumor metastasis. A novel molecule suppressed lung metastasis in mice without apparent side effects, suggesting a new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Tumor metastasis is a primary cause of cancer mortality.
- Claudin overexpression is common in malignant tumors, but claudin-targeting antimetastasis therapies are unexplored.
- A claudin-4-targeting molecule (C-CPE-fused PSIF) was previously developed.
Purpose of the Study:
- To investigate claudin CPE receptors as a target for antimetastasis therapy.
- To evaluate the efficacy of C-CPE-fused PSIF in preclinical metastasis models.
Main Methods:
- Utilized a claudin-4-targeting agent, C-CPE-fused PSIF.
- Employed a murine lung metastasis model using claudin-4-expressing B16 (CL4-B16) cells.
- Assessed effects on B16 cells and spontaneous metastasis of 4T1 breast cancer cells.
Main Results:
- C-CPE-fused PSIF suppressed lung metastasis of CL4-B16 cells but not wild-type B16 cells.
- The agent inhibited tumor growth and spontaneous lung metastasis of 4T1 cells.
- No significant side effects were observed in treated mice.
Conclusions:
- Claudin targeting represents a novel strategy for inhibiting certain types of tumor metastasis.
- C-CPE-fused PSIF demonstrates potential as an antimetastasis therapeutic agent.
- Further research into claudin-targeted therapies is warranted.
More Related Videos
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Cell Migration through Invadopodia
The Tumor Microenvironment
Mitogens and the Cell Cycle
Drugs that Stabilize Microtubules

